Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism

March 23, 2009 updated by: GAAD Medical Research Institute Inc.

Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.

A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.

Study Type

Interventional

Enrollment (Anticipated)

2

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M4V 1L5
        • The Centre for Incurable Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Persons with parathyroid disease

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: 1
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism.
Time Frame: 2 years
2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Kwasi Donyina, Ph.D., GAAD Medical Research Institute Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2007

Primary Completion (Anticipated)

March 1, 2009

Study Completion (Anticipated)

July 1, 2009

Study Registration Dates

First Submitted

December 12, 2007

First Submitted That Met QC Criteria

December 12, 2007

First Posted (Estimate)

December 14, 2007

Study Record Updates

Last Update Posted (Estimate)

March 24, 2009

Last Update Submitted That Met QC Criteria

March 23, 2009

Last Verified

March 1, 2009

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperparathyroidism

Clinical Trials on Far Infrared Radiation

3
Subscribe